Literature DB >> 16026244

Vaccine presentations and delivery technologies--what does the future hold?

C John Clements1, Steve L Wesselingh.   

Abstract

There is an urgent need to change the presentations and delivery technologies of current vaccines. Until recently, these factors had not been key criteria in the selection of vaccines for program use. Recent and current changes in the field of vaccines and their delivery lead the authors to postulate that a major paradigm shift will take place over the next decade to revolutionize vaccine presentation and delivery in national immunization programs. The programmatic needs for certain vaccine presentations will increasingly dictate elements of vaccine development and manufacture. Over the next decade, an inexorable drift towards firstly, single-dose preparations, and secondly, delivery technologies other than the conventional needle and syringes is anticipated. A unified system capable of delivering multiple antigens as a single dose is urgently needed; however, changing the status quo of vaccine manufacture is not easy. The market predominantly produces vaccines delivered by needle and syringe. Profits for manufacturers from sales to developing countries are marginal at best, and there is little financial incentive to change. Global leaders will need to take bold decisions and begin demanding vaccines which have a presentation that lends them to safer, more practical delivery systems. If a strong enough case can be made to restructure the vaccine manufacturing industry, either through market forces, global bodies, such as the World Health Organization and the United Nations Children's Fund, or both, a dramatic change could be brought about that will make vaccine delivery simpler and safer. A globally coordinated approach to funding research and the introduction of a multiple-antigen, single-dose delivery system is urgently needed. The needs are clear, and this review argues that if the case is presented strongly enough, the resources will be found.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16026244     DOI: 10.1586/14760584.4.3.281

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  3 in total

1.  Impact of changing the measles vaccine vial size on Niger's vaccine supply chain: a computational model.

Authors:  Tina-Marie Assi; Shawn T Brown; Ali Djibo; Bryan A Norman; Jayant Rajgopal; Joel S Welling; Sheng-I Chen; Rachel R Bailey; Souleymane Kone; Hailu Kenea; Diana L Connor; Angela R Wateska; Anirban Jana; Stephen R Wisniewski; Willem G Van Panhuis; Donald S Burke; Bruce Y Lee
Journal:  BMC Public Health       Date:  2011-06-02       Impact factor: 3.295

2.  Can a Compact Pre-Filled Auto-Disable Injection System (cPAD) Save Costs for DTP-HepB-Hib Vaccine as Compared with Single-Dose (SDV) and Multi-Dose Vials (MDV)? Evidence from Cambodia, Ghana, and Peru.

Authors:  Cyril Nogier; Patrick Hanlon; Karin Wiedenmayer; Nicolas Maire
Journal:  Drugs Real World Outcomes       Date:  2015-03

3.  Children who received PCV-10 vaccine from a two-dose vial without preservative are not more likely to develop injection site abscess compared with those who received pentavalent (DPT-HepB-Hib) vaccine: a longitudinal multi-site study.

Authors:  Yemane Berhane; Alemayehu Worku; Meaza Demissie; Neghist Tesfaye; Nega Asefa; Worku Aniemaw; Berhe Weldearegawi; Yigzaw Kebede; Tigist Shiferaw; Amare Worku; Lemessa Olijira; Behailu Merdekios; Yemane Ashebir; Takele Tadesse; Yadeta Dessie; Solomon Meseret; Gestane Ayele
Journal:  PLoS One       Date:  2014-06-04       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.